| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790090 | Urologic Oncology: Seminars and Original Investigations | 2018 | 11 Pages |
Abstract
High Ki67, EZH2, and SMYD3 immunoexpression, adjusted for standard clinicopathological parameters, independently predicts outcome in patients with PCa, at diagnosis. This might assist in discriminating indolent from aggressive PCa, improving treatment selection.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
João M.D., Ãngelo M.D., LuÃs M.Sc., Inês Ph.D., João B.Sc., Filipa Quintela Ph.D., Ana Teresa M.Sc., Jorge M.D., Carmen Ph.D., Rui M.D., Ph.D.,